Immunotherapy combined with bevacizumab and chemotherapy is a preferred option beyond RET‐TKIs in the first‐line therapy of RET‐arranged NSCLC, followed by the combination of bevacizumab and chemotherapy. The gene discussed is RET; the disease is non-small cell lung carcinoma.